GlassScriptPhysician profile
Luke Marcus Basdeo
NPI 1427491729
$56,376.99
in general payments reported to CMS, 2019-2025
19 companies · $5,283 in 2025
The $5,283 reported for 2025 was more than what 93% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54.39 · 2020: $39.77 · 2021: $302 · 2022: $419 · 2023: $37K · 2024: $13K · 2025: $5,283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $25K · Consulting Fee: $14K · Travel and Lodging: $11K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,150 · Food and Beverage: $2,803 · Education: $54.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $24,850.00 |
| Consulting Fee | $14,122.91 |
| Travel and Lodging | $10,581.98 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,150.00 |
| Food and Beverage | $2,802.75 |
| Education | $54.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Outset Medical INC | $54,440.14 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $442.12 | 2022-2025 | Acthar, Terlivaz |
| Horizon Therapeutics Plc | $217.75 | 2022-2023 | Krystexxa |
| Amgen INC. | $169.34 | 2020-2025 | Krystexxa, Tavneos |
| Vifor Pharma, INC. | $135.62 | 2022-2024 | Veltassa |
| Renalytix Ai, INC. | $133.82 | 2022-2025 | Kidneyintelx Blood Collection Convenience Kit |
| Otsuka America Pharmaceutical, INC. | $128.92 | 2022-2024 | Jynarque |
| Alnylam Pharmaceuticals INC. | $118.09 | 2021-2025 | Oxlumo |
| Fresenius USA Marketing, INC. | $114.68 | 2023-2025 | Velphoro, Velphoro |
| Astrazeneca Pharmaceuticals LP | $109.77 | 2022-2025 | Farxiga, Lokelma |
| Travere Therapeutics, INC. | $85.25 | 2023-2025 | Filspari |
| Ardelyx, INC. | $55.76 | 2023-2025 | Ibsrela |
| Veloxis Pharmaceuticals, INC. | $54.39 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $48.53 | 2022-2023 | |
| Calliditas Therapeutics US INC. | $34.47 | 2022-2023 | Tarpeyo |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $30.98 | 2020-2021 | |
| Opko Pharmaceuticals, LLC | $24.80 | 2025 | Rayaldee |
| Lilly USA, LLC | $21.77 | 2024 | Jardiance |
| Nuwellis, INC. | $10.79 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luke Basdeo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.